Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis

Journal of Experimental Medicine

Volumn 189, Issue 8, 1999, Pages 1229-1242

  Nieborowska Skorska, Malgorzata ^a   Wasik, Mariusz A ^b   Slupianek, Artur ^a   Salomoni, Paolo ^a   Kitamura, Toshio ^c   Calabretta, Bruno ^a,d   Skorski, Tomasz ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cooperation; Domains; Leukemia; Oncoprotein; Transformation

Indexed keywords

TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; DNA REPLICATION; DNA-BINDING PROTEINS; GENES, ABL; GENES, RAS; LEUKEMIA; MICE; MICE, SCID; MILK PROTEINS; MUTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; STAT5 TRANSCRIPTION FACTOR; STEM CELLS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS;

EID: 0033583530     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.8.1229     Document Type: Article

References (90)

1. Epner, D.E., and H.P. Koeffler. 1990. Molecular genetics of advances in chronic myelogenous leukemia. Ann. Intern. Med. 113:3-9.
2. Shtivelman, E., B. Lifshitz, R.P. Gale, B.A. Roe, and E. Canaani. 1986. Alternative splicing of RNAs transcribed from the human abl gene and from the BCR/ABL fused gene. Cell. 47:277-284.
3. 1-positive acute lymphoblastic leukemia (ALL). Science. 238:775-778.
4. Lugo, T.G., A.M. Pendergast, A.J. Mueller, and O.N. Witte. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1079-1083.
5. Bedi, A., B.A. Zehnbauer, J.P. Barberand, and S.J. Sharkis. 1994. Inhibition of apoptosis by BCR/ABL in chronic myelogenous leukemia. Blood. 83:2038-2044.
6. McGahon, A., R. Bissonnette, M. Schmitt, K.M. Cotter, D.R. Green, and T.G. Cotter. 1994. BCR/ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1179-1187.
7. Sirard, C., P. Laneuville, and J. Dick. 1994. Expression of BCR/ABL abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood. 83:1575-1585.
8. Verfaille, C.M., J.B. McCarthy, and P.B. McGlave. 1992. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. J. Clin. Invest. 90:1232-1249.
9. Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, M. Wasik, R. Trotta, P. Kanakaraj, P. Salomoni, M. Antonyak, R. Martinez, M. Majewski, et al. 1998. The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion and homing. Blood. 91:406-418.
10. bcr/abl gene of tne Philadelphia chromosome. Science. 247: 824-830.
11. Heisterkamp, N., G. Jenster, J. ten Hoeve, D. Zovich, P.K. Pattengale, and J. Groffen. 1990. Acute leukemia in bcr/abl transgenic mice. Nature. 344:251-253.
12. Kelleher, M.A., J. McLaughlin, O.N. Witte, and N. Rosenberg. 1990. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA. 87:6649-6653.
13. Raitano, A.B., Y.E. Whang, and C.L. Sawyers. 1997. Signal transduction by wild-type and leukemic Ab1 proteins. Biochim. Biophys. Acta. 1333:F201-F216.
14. Sattler, M., and R. Salgia. 1997. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 8:63-79.
15. bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J. Exp. Med. 179:1855-1865.
16. Sawyers, C.L., J. McLaughlin, and O.N. Witte. 1995. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the BCR/ABL oncogene. J. Exp. Med. 181:307-313.
17. Skorski, T., P. Wlodarski, L. Daheron, P. Salomoni, M. Nieborowska-Skorska, M. Majewski, M. Wasik, and B. Calabretta. 1998. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Sci. USA. 95:11858-11862.
18. Skorski, T., M. Nieborowska-Skorska, C. Szczylik, P. Kanakaraj, D. Perrotti, G. Zon, A.M. Gewirtz, B. Perussia, and B. Calabretta. 1995. c-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res. 55:2275-2278.
19. Varticovski, I., G.Q. Daley, P. Jackson, D. Baltimore, and L. Cantley. 1991. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol. Cell. Biol. 11: 1107-1113.
20. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M.Z. Ratajczcak, S.-C. Wen, G. Zon, A.M. Gewirtz, B. Perussia, and B. Calabretta. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 86:726-736.
21. Skorski, T., A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, J.K. Choi, R. Trotta, P. Wlodarski, D. Perrotti, T.O. Chen, et al. 1997. Transformation of hematopoietic cells by BCR/ABL requires the activation of a PI-3k/Akt-dependent pathway. EMBO (Eur. Mol. Biol. Organ.) J. 16:6151-6161.
22. Sanchez-Garcia, I., and G. Grutz. 1995. Tumorigenic activity of the BCR/ABL oncogenes is mediated by BCL-2. Proc. Natl. Acad. Sci. USA. 92:5287-5291.
23. Reuther, J.Y., G.W. Reuther, D. Cortez, A.M. Pendergast, and A.S. Baldwin, Jr. 1998. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev. 12: 968-981.
24. Carlesso, N., D.A. Frank, and J.D. Griffin. 1996. Tyrosine phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR/ABL. J. Exp. Med. 183:811-820.
25. Frank, D.A., and L. Varticovski. 1996. BCR/ABL leads to the constitutive activation of STAT proteins, and shares an epitope with tyrosine phosphorylated STAT'5. Leukemia. 10: 1724-1730.
26. bcr/abl induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:31704-31710.
27. Shuai, K., J. Halpern, J. ten Harve, X. Rao, and C.L. Sawyers. 1996. Constitutive activation of STAT5 by the BCR/ABL oncogene in chronic myelogenous leukemia. Oncogene. 13:247-254.
28. Ihle, J.N. 1996. STATs: signal transducers and activation of transcription. Cell. 84:331-334.
29. Darnell, J.E. 1997. STATs and gene regulation. Science. 277: 1630-1635.
30. Liu, X., G.W. Robinson, K.V. Wagner, L. Garnet, A. Wynshaw-Boris, and L. Hennighausen. 1997. STAT5A is mandatory for adult gland development and lactogenesis. Genes Dev. 9:2266-2278.
31. Udy, G.B., R.G. Snell, R.J. Wilkins, S.-H. Park, P.A. Ra, D.J. Waxman, and H.W. Davey. 1997. Requirement of STAT5B for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. USA. 94:7239-7244.
32. Teglund, S., C. McKay, E. Schuetz, J.M. van Deursen, D. Stravopodis, D. Wang, M. Brown, S. Bodner, G. Grosveld, and J.N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:841-850.
33. Lin, J.X., T.S. Migone, M. Tsang, M. Friedmann, J.A. Weatherbee, L. Zhou, A. Yamauchi, E.T. Bloom, J. Mietz, and S. John. 1995. The role of shared receptor motifs and common STAT proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity. 2:331-339.
34. Zamorano, J., M.Y. Wang, R. Wang, Y. Shi, G.D. Longmore, and A.D. Keegan. 1998. Regulation of cell growth by IL-2: role of STAT5 in protection from apoptosis but not in cell cycle progression. J. Immunol. 160:3502-3512.
35. Azam, M., H. Erdument-Bormage, B.L. Krieder, M. Xia, F. Quelle, R. Basu, C. Saris, P. Tempst, J.N. Ihle, and C. Schindler. 1995. Interleukin-3 signals through multiple isoforms of STAT5. EMBO (Eur. Mol. Biol. Organ.) J. 14:1402-1411.
36. Mui, A.L., H. Wakeo, A. O'Farrell, N. Harada, and A. Miyajima. 1995. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 signals through two STAT5 homologs. EMBO (Eur. Mol. Biol. Organ.) J. 14: 1166-1175.
37. Wakao, H., N. Harada, T. Kitamura, A.L. Mui, and A. Miyajima. 1995. Interleukin-2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO (Eur. Mol. Biol. Organ.) J. 14:2527-2535.
38. Sawka-Verhelle, D., C. Filloux, S. Tartare-Deckert, I. Mothe, and E. van Obberghen. 1997. Identification of STAT5b as a substrate of the insulin receptor. Eur. J. Biochem. 250:411-417.
39. Zhong, Z., Z. Wen, and J.E. Darnell. 1994. STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95-98.
40. Waxman, D.J., P.A. Ram, S.H. Park, and H. K. Choi. 1995. Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver expressed, STAT5-related DNA binding protein. J. Biol. Chem. 270: 13262-13270.
41. Boccaccio, C., M. Ando, L. Tamagnone, A. Bardelli, P. Michieli, C. Battistini, and P.M. Comoglio. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 391:285-288.
42. Danial, N.N., A. Pernis, and P.B. Rothman. 1995. JakSTAT signalling induced by the v-abl oncogene. Science. 269: 1875-1877.
43. Chaturvedi, P., S. Sharma, and E.P. Reddy. 1997. Abrogation of interleukin-3 dependence of myeloid cells by v-src oncogene requires SH2 and SH3 domains which specify activation of STAT. Mol. Cell. Biol. 17:3295-3304.
44. Yu, C.L., R. Jove, and S.J. Burakoff. 1997. Constitutive activation of the Janus kinase-STAT pathway in T-lymphoma overexpressing the Lck protein tyrosine kinase. J. Immunol. 159:5206-5210.
45. Saharinen, P., N. Ekman, K. Sarvas, P. Parker, K. Alitalo, and O. Silvennoinen. 1997. The Bmx tyrosine kinase induces activation of the STAT signalling pathway, which is specifically inhibited by protein kinase. Blood. 90:4341-4353.
46. Wen, Z., Z. Zhong, and J.E. Darnell. 1995. Maximal activation of transcription of STAT1 and STAT3 requires both tyrosine and serine phosphorylation. Cell. 82:241-250.
47. Zhang, X., J. Blenis, H.C. Li, C. Schindler, and S. Chen-Kiang. 1995. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 267:1990-1994.
48. Mui, A.L., H. Wakeo, T. Kinoshita, T. Kitamura, and A. Miyajima. 1996. Suppression of interleukin-3-induced gene expression by a C-terminal truncated STAT5: role of STAT5 in proliferation. EMBO (Eur. Mol. Biol. Organ.) J. 15:2425-2433.
49. Wang, D., D. Stravopodis, S. Teglund, J. Kitarawa, and J.N. Ihle. 1996. Naturally occurring dominant negative variants of STAT5. Mol. Cell. Biol. 16:6141-6148.
50. Meyer, J., M. Jucker, W. Ostertag, and C. Stocking. 1998. Carboxyl-truncated STAT5b is generated by a nucleus-associated serine protease in early hematopoietic progenitors. Blood. 91:1901-1908.
51. Hara, T., and A. Miyajima. 1996. Function and signal transduction mediated by the interleukin-3 receptor system in hematopoiesis. Stem Cells. 14:605-618.
52. Feldman, G.M., L.A. Rosenthal, X. Lui, M.P. Hayes, S.A. Wynshaw-Borios, W.S. Leonard, L. Hennighausen, and D.S. Finbloom. 1997. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. 90:1768-1776.
53. Gouilleux-Gouart, V., F. Gouilleux, C. Desaint, J.F. Claisse, J.C. Capiod, J. Delobel, R. Weber-Noralt, I. Dusanter-Fourt, F. Dreyfus, B. Groner, and L. Prin. 1996. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 87: 1692-1697.
54. Zhang, Q., I. Nowak, E.C. Vanderheid, A.M. Rook, M.E. Kadin, P.C. Nowell, L.M. Shaw, and M.A. Wasik. 1996. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin-2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA. 93:9148-9153.
55. Chai, S.K., G.L. Nichols, and P. Rothman. 1997. Constitutive activation of JAKs and STATs in BCR/ABL-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159:4720-4728.
56. Cortez, D., L. Kadlec, and A.M. Pendergast. 1995. Structural and signalling requirements for BCR/ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15: 5531-5541.
57. Pendergast, A.M., A.J. Muller, M.H. Havlik, Y. Maru, and O.N. Witte. 1991. BCR sequences essential for transformation by the BCR/ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 66:161-171.
58. Onishi, M., T. Nosaka, K. Misawa, A.L.F. Mui, D.M. Gorman, M. McMahon, A. Miyajima, and T. Kitamura. 1998. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18:3871-3879.
59. Greenberger, J.S., M.A. Sakakeeny, R.K. Humphries, C.J. Eaves, and R.J. Eckner. 1983. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/eosinophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. USA. 80:2931-2935.
60. bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA. 93: 13137-13142.
61. Pear, W.S., G.P. Nolan, M.L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90:8392-8396.
62. Davis, R.L., J.B. Konopka, and O.N. Witte. 1985. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol. Cell. Biol. 5:204-213.
63. Skorski, T., M. Nieborowska-Skorska, K. Campbell, R.V. Iozzo, G. Zon, Z. Darzynkiewicz, and B. Calabretta. 1995. Leukemia treatment in severe combined immunodeficient mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J. Exp. Med. 182:1645-1653.
64. Van Etten, R.A., J. Debnath, H. Zhou, and J.M. Casanovas. 1995. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene. 10:1977-1988.
65. Mayer, B.J., P.K. Jackson, R.A. Van Etten, and D. Baltimore. 1992. Point mutations in the ABL SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12:609-618.
66. Ham, H.-J., W.G. Haser, T.M. Roberts, and C.A. Frederick. 1996. Intramolecular interactions of the regulatory domains of the BCR/ABL kinase reveal a novel control mechanism. Structure. 4:1105-1114.
67. Han, L., and J. Colicelli. 1995. A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf 1. Mol. Cell. Biol. 15:1318-1323.
68. Afar, D.E.M., L. Han, J. McLaughlin, S. Wong, A. Dhaka, K. Parmar, N. Rosenberg, O.N. Witte, and J. Colicelli. 1997. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity. 6:773-782.
69. Danial, N.N., J.A. Losman, T. Lu, N. Yip, K. Krishnan, J. Krolewski, S.P. Goff, J.Y. Wang, and P.B. Rothman. 1998. Direct interaction of Jak 1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation. Mol. Cell. Biol. 18:6795-6804.
70. L. Oncogene. 16: 1383-1390.
71. Cortez, D., G. Stoica, J.H. Pierce, and A.M. Pendergast. 1996. The BCR/ABL tyrosine kinase inhibits apoptosis by activating a RAS-dependent signaling pathway. Oncogene, 13: 2589-2594.
72. Salomoni, P., M.A. Wasik, R.F. Riedel, K. Reiss J.K. Choi, T. Skorski, and B. Calabretta. 1998. Expression of constitutively active Raf-1 in the mitochondria restores anti-apoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J. Exp. Med. 187:1995-2007.
73. Boucheron, C., S. Dumon, S.C. Santos, R. Moriggl, L. Hennighausen, S. Gisselbrecht, and F. Gouilleux. 1998. A single amino acid in the DNA binding regions of STAT5A and STAT5B confers distinct DNA binding specificities. J. Biol. Chem. 273:33936-33941.
74. Lin, E.Y., A. Orlofsky, M.S. Berger, and M.R. Prystowsky. 1993. Characterization of A1, a novel hematopoietic-specific early-response gene with sequence similarity to bcl-2. J. Immunol. 151:1979-1986.
75. Liu, L., J.E. Damen, M.R. Hughes, I. Babic, F.R. Jirik, and G. Krystal. 1997. The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis. J. Biol. Chem. 272:8983-8988.
76. Sattler, M., R. Salgia, G. Shrikhande, S. Verma, J.L. Choi, L.R. Rohrschneider, and J.D. Griffin. 1997. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 15:2379-2386.
77. Ota, J., F. Kimura, K. Sato, N. Wakimoto, Y. Nakamura, N. Nagata, S. Suzu, M. Yamada, S. Shimamura, and K. Motoyoski. 1998. Association of CrkL with STAT5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythroprotein. Biochem. Biophys. Res. Commun. 252:779-786.
78. Matsumoto, A., M. Masuhara, K. Mitsui, M. Yokonchi, M. Ohtsubo, H. Misawa, A. Miyajima, and A. Yoshimura. 1997. CIS, a cytokine inducible SH2 protein is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 89: 3148-3154.
79. Cortez, D., G. Reuther, and A.M. Pendergast. 1997. The BCR-ABL tyrosine kinase activates mitogenic signalling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 15:2333-2342.
80. Kabarowski, J.M.S., P.B. Allen, and L.M. Wiedermann. 1994. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO (Eur. Mol. Biol. Organ.) J. 13:5887-5895.
81. Goga, A., J. McLaughlin, D.E. Afar, D.C. Saffran, and O.N. Witte. 1995. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82:981-988.
82. Sirard, C., P. Laneuville, and J.E. Dick. 1994. Expression of bcr-abl abrogate factor-dependent growth of human hematopoietic MO7E cells by an autocrine mechanisms. Blood. 83: 1575-1585.
83. Anderson, S.M., and J. Mladenovic. 1996. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Blood. 87:238-244.
84. Klucher, K.M., D.V. Lopez, and G.Q. Daley. 1998. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 91:3927-3934.
85. Lin, E.Y., A. Orlofsky, H.-G. Wang, J.O. Reed, and M.R. Prystowsky. 1996. A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation. Blood. 87:983-992.
86. D'Sa-Eipper, C., T. Subramanian, and G. Chimnaduvai. 1996. Bfl-1, a bcl-2 homologue, suppresses p53 induced apoptosis and exhibits potent cooperative-transforming activity. Cancer Res. 56:3879-3882.
87. van Lohuizen, M., S. Verbeek, P. Krimpenfort, J. Domen, C. Saris, T. Radeszkiewicz, and A. Berns. 1989. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 56:673-682.
88. Leverson, J.D., P.J. Koskinen, F.C. Orrico, E.-M. Rainio, K.J. Jalkanen, A.B. Dash, R.N. Eisenman, and S.A. Ness. 1998. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol. Cell. 2:417-425.
89. Sawyers, C.L., W. Callahan, and O.N. Witte. 1992. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 70:901-910.
90. Calabretta, B., R.B. Sims, M. Valtieri, D. Caracciolo, C. Szczylik, D. Venturelli, M. Ratajczak, M. Beran, and A.M. Gewivtz. 1991. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. USA. 88:2351-2355.